INTEGRA LIFESCIENCES HOLDINGS CORP(IART)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,740 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in IART
Events flagged as statistical outliers against IART's own multi-year baseline — not fixed dollar thresholds.
IART Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for INTEGRA LIFESCIENCES HOLDINGS CORP (IART), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IART at 48.2/100 on a 32-signal composite quality model, placing it at rank #1,740 of 2,962 stocks — the bottom half of the AI-ranked universe. IART scores in the top quartile across earnings quality (97.4). Areas of concern include institutional flow (15.1) and free cash flow (30.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), INTEGRA LIFESCIENCES HOLDINGS CORP reports quarterly revenue of $418.8M, net income of $4.5M, an operating margin of 4.6%. Top institutional holders of IART by reported 13-F value include BlackRock, Rubric Capital Management, Invesco Ltd., based on the most recent SEC filings. IART trades on the Nasdaq exchange and files with the SEC under CIK 917520. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IART daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INTEGRA LIFESCIENCES HOLDINGS CORP directly from SEC EDGAR. INTEGRA LIFESCIENCES HOLDINGS CORP's 13F Pro composite quality score has ranged between 31 and 63 since 2021, currently 48.2 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$418.8M
Net Income
Q2 2026
$4.5M
Free Cash Flow
Q2 2026
$10.5M
Operating Margin
Q2 2026
4.6%
ROIC
Q2 2026
4.4%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+1.5% YoYNet Income
-7337.7% YoYOperating Income
-1836.5% YoYEPS (Diluted)
-7388.9% YoYTotal Assets
-10.8% YoYTotal Debt
-4.5% YoYOp. Cash Flow
-61.1% YoYFree Cash Flow
-224.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.64B +1.5% | $1.61B +4.5% | $1.54B -1.0% | $1.56B +1.0% | $1.54B +12.4% | $1.37B |
| Net Income | $-516.5M -7337.7% | $-6.9M -110.3% | $67.7M -62.5% | $180.6M +6.8% | $169.1M +26.3% | $133.9M |
| Operating Income | $-493.4M -1836.5% | $28.4M -74.5% | $111.5M -53.3% | $238.9M +21.1% | $197.2M +30.3% | $151.4M |
| EPS (Diluted) | $-6.74 -7388.9% | $-0.09 -110.7% | $0.84 -61.1% | $2.16 +9.1% | $1.98 +26.1% | $1.57 |
| Total Assets | $3.60B -10.8% | $4.04B +6.8% | $3.78B -2.8% | $3.89B +2.8% | $3.78B +4.6% | $3.62B |
| Total Debt | $726.6M -4.5% | $760.5M -1.9% | $775.0M +0.0% | $775.0M -8.1% | $843.8M -3.8% | $877.5M |
| Operating Cash Flow | $50.4M -61.1% | $129.4M -7.6% | $140.0M -47.1% | $264.5M -15.4% | $312.4M +53.3% | $203.8M |
| Free Cash Flow | $-31.1M -224.4% | $25.0M -65.8% | $73.1M -67.1% | $222.1M -16.0% | $264.4M +60.3% | $164.9M |
Get alerted when IART's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for INTEGRA LIFESCIENCES HOLDINGS CORP including:
Top Institutional Holders of IART
BlackRock, Inc.
$191.9M10,684,103 shRubric Capital Management LP
$139.3M7,753,934 shInvesco Ltd.
$67.3M3,749,367 shVANGUARD PORTFOLIO MANAGEMENT LLC
$67.2M3,743,093 shMORGAN STANLEY
$64.5M3,593,079 shPARADIGM CAPITAL MANAGEMENT INC/NY
$61.8M3,439,098 shFULLER & THALER ASSET MANAGEMENT, INC.
$61.7M3,436,006 shSTATE STREET CORP
$52.9M2,946,862 shVANGUARD CAPITAL MANAGEMENT LLC
$52.9M2,946,173 shNeuberger Berman Group LLC
$42.6M2,364,777 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $191.9M | 10,684,103 |
| Rubric Capital Management LP | $139.3M | 7,753,934 |
| Invesco Ltd. | $67.3M | 3,749,367 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $67.2M | 3,743,093 |
| MORGAN STANLEY | $64.5M | 3,593,079 |
| PARADIGM CAPITAL MANAGEMENT INC/NY | $61.8M | 3,439,098 |
| FULLER & THALER ASSET MANAGEMENT, INC. | $61.7M | 3,436,006 |
| STATE STREET CORP | $52.9M | 2,946,862 |
| VANGUARD CAPITAL MANAGEMENT LLC | $52.9M | 2,946,173 |
| Neuberger Berman Group LLC | $42.6M | 2,364,777 |
Companies Similar to IART
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CONMED Corp
NEOGEN CORP
QuidelOrtho Corp
ANGIODYNAMICS INC
AdaptHealth Corp.
Envista Holdings Corp
Enovis CORP
Huntsman CORP
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put IART on your watchlist
Track score changes the day INTEGRA LIFESCIENCES HOLDINGS CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IART a good stock to buy?
13F Pro's AI-powered analysis of INTEGRA LIFESCIENCES HOLDINGS CORP (IART) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IART are available on the IART stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IART is classified as a small company.
Which hedge funds own IART?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IART. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INTEGRA LIFESCIENCES HOLDINGS CORP's investment landscape.